A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

A proof-of-concept study on the genomic evolution of SARS-CoV-2 during antiviral treatment reveals that Molnupiravir induces a higher in vivo intra-host variability compared to Paxlovid and drug-naive.

Bibliographic Details
Main Authors:	Claudia Alteri, Valeria Fox, Rossana Scutari, Giulia Jole Burastero, Sara Volpi, Matteo Faltoni, Vanessa Fini, Annarita Granaglia, Sara Esperti, Altea Gallerani, Valentino Costabile, Beatrice Fontana, Erica Franceschini, Marianna Meschiari, Andrea Campana, Stefania Bernardi, Alberto Villani, Paola Bernaschi, Cristina Russo, Giovanni Guaraldi, Cristina Mussini, Carlo Federico Perno
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-12-01
Series:	Communications Biology
Online Access:	https://doi.org/10.1038/s42003-022-04322-8

Similar Items

Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
by: Andrea J. Haddad, et al.
Published: (2024-03-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia
by: Rossana Scutari, et al.
Published: (2023-03-01)

Is It Possible to Eradicate Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) from Endemic Hospitals?
by: Filippo Medioli, et al.
Published: (2022-07-01)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
by: Wen Wen, et al.
Published: (2022-12-01)

Epidemiology and Prevention of Early Infections by Multi-Drug-Resistant Organisms in Adults Undergoing Liver Transplant: A Narrative Review
by: Giovanni Dolci, et al.
Published: (2023-06-01)

Molnupiravir; an effective drug in treating COVID-19?
by: Alireza Pouramini, et al.
Published: (2022-01-01)

The Path to Paxlovid
by: Bethany Halford
Published: (2022-04-01)

Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children
by: Rossana Scutari, et al.
Published: (2024-03-01)

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
by: Giulia Jole Burastero, et al.
Published: (2022-07-01)

28 Experiences of using Paxlovid to treat clinically extremely vulnerable non-hospitalised patients with COVID-19
by: Joshua Gahir, et al.
Published: (2022-09-01)

Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib
by: Vanyo Mitev
Published: (2023-10-01)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patients
by: Aaisha Shah, et al.
Published: (2022-09-01)

Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients
by: Luna Colagrossi, et al.
Published: (2022-11-01)

Identification of the <i>bla</i><sub>OXA-23</sub> Gene in the First Mucoid XDR <i>Acinetobacter baumannii</i> Isolated from a Patient with Cystic Fibrosis
by: Martina Rossitto, et al.
Published: (2023-10-01)

A rare case of necrotizing fasciitis of the leg in an intravenous drug user caused by Prevotella denticola
by: Andrea Bedini, et al.
Published: (2024-12-01)

Computational Analysis of Molnupiravir
by: Artem V. Sharov, et al.
Published: (2022-01-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

The Role of HIV Infection in Neurologic Injury
by: Rossana Scutari, et al.
Published: (2017-04-01)

Activation of PXR causes drug interactions with Paxlovid in transgenic mice
by: Saifei Lei, et al.
Published: (2023-11-01)

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
by: Yang W, et al.
Published: (2024-03-01)

Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
by: Claudia Alteri, et al.
Published: (2022-06-01)

Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
by: Claudia Alteri, et al.
Published: (2022-07-01)

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
by: Peng Su, et al.
Published: (2024-01-01)

Public Health Impact of Paxlovid as Treatment for COVID-19, United States
by: Yuan Bai, et al.
Published: (2024-02-01)

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
by: Sarah Mohamed, et al.
Published: (2023-09-01)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
by: P. Periyasamy, et al.
Published: (2023-05-01)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2023-06-01)

Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
by: Weina Zhang, et al.
Published: (2023-06-01)

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
by: Mohamad Reza Mobinizadeh, et al.
Published: (2022-10-01)

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
by: Alireza Pouramini, et al.
Published: (2022-07-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

Why Molnupiravir Fails in Hospitalized Patients
by: Ashley N. Brown, et al.
Published: (2022-12-01)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023-11-01)

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
by: Rossana Scutari, et al.
Published: (2020-03-01)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
by: Qinyue Zheng, et al.
Published: (2023-04-01)

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
by: Keisuke Nakamura, et al.
Published: (2022-11-01)

Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient
by: Robert D. Maynard, et al.
Published: (2023-08-01)

Molnupiravir: Mechanism of action, clinical, and translational science
by: Brian M. Maas, et al.
Published: (2024-02-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)